Read UMR's July 13 Statement on NIH Funding in House Labor-HHS Appropriations Bill
NIH Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
NIH's Role In Sustaining the U.S. Economy | 2023 Update Now Available
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Johnson & Johnson to begin human trials for coronavirus vaccine in late July, earlier than expected

Johnson & Johnson announced Wednesday its early-stage human trial for a potential coronavirus vaccine will begin in the second half of July, earlier than its initial forecast of September.

“Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant,” J&J’s Chief Scientific Officer Paul Stoffels said in a press release.